Association between transforming growth factor β1 genetic polymorphism and response to chemoradiotherapy in head and neck squamous cell cancer

Head and Neck

Volumn 31, Issue 5, 2009, Pages 664-672

  Lundberg, Marie ^a   Pajusto, Mervi ^a   Koskinen, Walter J ^a   Mäkitie, Antti A ^a   Aaltonen, Leena Maija ^a   Mattila, Petri S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Genetic polymorphism; Head and neck squamous cell carcinoma; Neoplastic stem cells; Radiotherapy; Transforming growth factor beta

Indexed keywords

CISPLATIN; MITOMYCIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE; FOLLOW UP; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 66349109789     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21014     Document Type: Article

References (29)

1. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-159. (Pubitemid 32060666)
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. New Engl J Med 2001;345:1890-1900. (Pubitemid 33716564)
3. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. New Engl J Med 2000;342:1350-1358. (Pubitemid 30408720)
4. Akhurst RJ, Derynck R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 2001;11:S44-S51. (Pubitemid 33001443)
5. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005;23:2078-2093. (Pubitemid 46211385)
6. Atfi A, Baron R. p53 brings a new twist to the Smad signaling network. Sci Signal 2008;1:pe33.
7. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A 2003;100:8621-8623. (Pubitemid 36899145)
8. Tang B, Vu M, Booker T, et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 2003;112:1116-1124. (Pubitemid 38056326)
9. Kaklamani VG, Pasche B. Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 2004;4:649-661. (Pubitemid 39161996)
10. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-2615. (Pubitemid 36605203)
11. Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y. Association of a T29->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000;101:2783-2787. (Pubitemid 30396007)
12. Kaklamani VG, Baddi L, Liu J, et al. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res 2005;65:3454-3461. (Pubitemid 40524632)
13. Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE. T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers 2004;13:412-415. (Pubitemid 38737467)
14. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: the Study of Osteoporotic Fractures. JAMA 2001;285:2859-2863. (Pubitemid 32537349)
15. Saarilahti K, Kouri M, Collan J, et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol 2005;74:251-258. (Pubitemid 40349134)
16. Saarilahti K, Kajanti M, Atula T, et al. Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. Am J Clin Oncol 2004;27:589-1504 (Pubitemid 39603274)
17. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999;8:93-97. (Pubitemid 29039053)
18. Raynal S, Nocentini S, Croisy A, Lawrence DA, Jullien P. Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer 1997;72:356-361. (Pubitemid 27314898)
19. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008;26:2839-2845.
20. Prince ME, Ailles LE. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 2008;26:2871-2875.
21. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715.
22. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-273. (Pubitemid 46349843)
23. Shu XO, Gao YT, Cai Q, et al. Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res 2004;64:836-839. (Pubitemid 38176881)
24. Gonzalez-Zuloeta Ladd AM, Arias-Vasquez A, Siemes C, et al. Transforming-growth factor beta1 Leu10Pro polymorphism and breast cancer morbidity. Eur J Cancer 2007;43:371-374. (Pubitemid 46123980)
25. Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S. Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 2000;20:4413-4418. (Pubitemid 32141796)
26. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-1719. (Pubitemid 29513039)
27. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998;37:19-29. (Pubitemid 28385181)
28. Akhurst RJ. TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 2002;109:1533-1536.
29. Wei YS, Zhu YH, Du B, et al. Association of transforming growth factor-beta1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 2007;380:165-169. (Pubitemid 46498056)